AstraZeneca to invest $2B in Summit Therapeutics, testing ivonescimab with its ADCs
The equity investment gives AstraZeneca a role in developing Summit's PD-1/VEGF bispecific without ownership rights, deepening the race in that drug class.
STAT · +10 outlets
uniQure shares fall as four-year Huntington's gene therapy data underwhelm investors
Analysts said investors wanted stronger durability from AMT-130, undercutting a key approval-supporting trial; some saw filing data at three years as stronger.
Biopharmadive · +6 outlets
Merck to pay up to $2.6B-equivalent range deals as Novo, others bet on Chinese biotech
Novo agreed to pay Hengrui up to $2.6B for a once-weekly obesity pill and Merck inked a $2.1B oncology deal, adding to a wave of Western licensing of Chinese as
Biopharmadive · +2 outlets
Eli Lilly reports phase 3 retatrutide data, setting up next-gen obesity battle
Full late-stage data for the triple agonist arrives as Lilly and Novo compete on next-generation weight loss drugs.
Fierce Biotech · +14 outlets
Beam Therapeutics sues YolTech and Serapha, alleging theft of base editing trade secrets
Beam claims a former scientist took confidential information to co-found a Chinese company that licensed a rival rare disease therapy; Serapha denies the charge
Biopharmadive · +6 outlets
Trump's final Medicare drug pricing rule applies to four companies, saves 96% less than proposed
The watered-down Global Benchmark rule covers drugs administered in doctor offices and falls far short of the savings in the initial proposal.
STAT · +1 outlets
HHS announces ARPA-H efforts to speed and expand clinical trials with AI
Federal health officials aim to accelerate clinical research to compete with countries like China; Anthropic joins the ARPA-H clinical AI effort.
STAT · +8 outlets
Lilly's Zepbound combined with amylin drug yields significant weight loss in mid-stage trial
High discontinuation rates in the combination study raise questions about tolerability for the investigational therapy.
STAT · +14 outlets
FDA approves Ultragenyx's gene therapy, first Sanfilippo syndrome type A treatment
The approval marks the first therapy for the rare pediatric neurodegenerative disease.
The Medicine Maker · +14 outlets
PhRMA names former congressman Eric Cantor as next CEO
Cantor takes the helm of the industry lobbying group at a challenging time for pharma, succeeding Steve Ubl.
STAT · +5 outlets
HLB wins FDA approval for bile duct cancer drug rivoceranib, a first for a Korean firm
HLB becomes the first Korean company to directly secure FDA anticancer drug approval and plans to resubmit a liver cancer application next month.
finance.biggo.com · +4 outlets
Merck and Daiichi withdraw small cell lung cancer drug bid after FDA signals phase 2 data fell short
The companies pulled the application after regulators indicated the mid-stage data did not support approval.
inkl · +6 outlets
FDA starts review of Roche's fenebrutinib, a multiple sclerosis pill
The agency had never accepted an application for a BTK inhibitor in two major forms of MS, though safety questions hang over the program.
Biopharmadive · +5 outlets
Bristol Myers trial revisions shake confidence in new class of fibrosis drugs
A spokesperson confirmed a limited number of liver-related safety events, including a patient death, in testing of admilparant, though causation is unclear.
Biopharmadive · +2 outlets
UnitedHealth investor lawsuit advances on claims it 'manufactured earnings'
A federal judge declined to dismiss allegations that the insurer hid declining profits.
STAT · +1 outlets
Citi downgrades Moderna to sell, says oncology optimism is priced in after 222% rally
The downgrade sent Moderna shares down about 6%, with Merck and Pfizer flat.
Yahoo! Finance Canada · +9 outlets
Merck in oncology pipeline expansion with $2.1B Chinese biotech deal
The deal adds to a run of Western pharma licensing agreements for Chinese-developed cancer assets.
TradingView · +1 outlets
Iovance raises FY2026 revenue outlook, shares hit over two-year high
The cancer therapy maker's improved forecast lifted the stock sharply.
tradingview.com · +3 outlets